Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...

Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...

Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...

As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...

London-based women’s health pharma Theramex has agreed to pay up to $250 million to license Shanghai-based Asieris’ first-in-class non-surgical treatment for cervical precancerous lesions associated ...

A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...

A U.K. drug marketing watchdog has slammed CSL Seqirus for “multiple and prolonged deficiencies” in its systems, governance ...

After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...

NBA Champion Karl-Anthony Towns knows both ball and COVID-19. | New York Knicks champ Karl-Anthony Towns is sharing his personal experience with COVID to encourage others to talk with their doctors ...

The successes of the GLP-1 class for chronic weight management “introduced consumer overlay over a historically physician-driven therapeutic area,” Pothier explained, noting that despite the potency ...

The National Fragility Index, launched by the API Innovation Center, warns that more than 550 million prescriptions filled in the U.S. in 2023 were for drugs ranked as having high or severe ...

Catalent is vying for a stronger foothold in next-gen drug development, and it's betting on developer's need for speed. | ...